As the interaction of the well-established oncogene SHP-2 with phosphorylated IDO1 increased in FTC-133 cells in response to the catalytic inhibitors, we explored the functional effects triggered by IDO1/SHP-2 complexes in the tumor cells. The gene discussed is IDO1; the disease is neoplasm.